下调胰岛素样生长因子抑制miR-767-5p的表达对乳腺癌细胞增殖、迁移、侵袭及上皮间充质转化的影响

doi:10.3969/j.issn.1006-5725.2023.22.004

摘要/Abstract

摘要：

目的研究抑制miR-767-5p对乳腺癌细胞增殖、迁移、侵袭和上皮间充质转化（EMT）的影响。方法体外培养乳腺癌细胞，将miR-767-5p inhibitor和inhibitor-NC转染到乳腺癌细胞中。细胞分为3组：空白对照组（Control组），miR-767-5p inhibitor组和inhibitor-NC组，采用CCK-8法、Transwell法、划痕实验检测miR-767-5p抑制剂对乳腺癌细胞增殖、侵袭和迁移能力的影响。Western blot检测迁移相关蛋白基质金属蛋白酶-2（MMP-2）和MMP-9的表达水平。双荧光素酶报告基因实验验证miR-767-5p和胰岛素样生长因子-1（IGF1）的靶向结合作用。RT-qPCR和Western blot实验检测IGF1 mRNA和蛋白的表达水平。采用Western blot检测EMT相关蛋白的表达水平。结果 CCK-8实验结果显示，与Control组和inhibitor-NC组相比，miR-767-5p inhibitor组显著抑制MCF-7细胞的增殖（P < 0.05）。Transwell实验结果表明，与Control组和inhibitor-NC组相比，miR-767-5p inhibitor组乳腺癌细胞侵袭细胞数显著下降（P < 0.05）。划痕实验结果显示，与Control组和inhibitor-NC组相比，miR-767-5p inhibitor组乳腺癌细胞迁移率显著下降（P < 0.05）。荧光素酶报告基因实验结果显示，miR-767-5p能够靶向结合IGF1。Western blot结果表明，与Control组和inhibitor-NC组相比，miR-767-5p inhibitor组的E-cadherin蛋白表达水平显著增高（P < 0.05），N-cadherin、MMP-2和MMP-9蛋白的表达水平显著降低（P < 0.05）。与Control组和inhibitor-NC组相比，miR-767-5p inhibitor组中IGF1的mRNA和蛋白表达水平显著降低（P < 0.05）。结论抑制miR-767-5p的表达可通过下调IGF1抑制乳腺癌细胞的增殖、侵袭、迁移及EMT的发生。

关键词: 乳腺癌, miR-767-5p, 胰岛素样生长因子-1, 上皮间充质转化, 迁移侵袭

Abstract:

Objective To investigate the effect of inhibiting miR-767-5p on migration， invasion and epithelial-mesenchymal transition（EMT） of breast cancer cells. Methods Breast cancer cells were cultured in vitro， and miR-767-5p inhibitor and inhibitor NC were transfected into breast cancer cells. The cells were divided into three groups： Control group， miR-767-5p inhibitor group and inhibitor-NC group. The effects of miR-767-5p inhibitor on the proliferation， invasion and migration of breast cancer cells were detected by CCK-8 assay， Transwell Migration assay and scratch test. Western blot was used to detect the expression levels of migration related proteins MMP-2 and MMP-9. The dual luciferase reporter gene experiment verifies the targeted binding effect of miR-767-5p and IGF1. RT-qPCR and Western blot experiments were used to detect the expression levels of IGF1 mRNA and protein. Western blot was used to detect the expression level of EMT related proteins. Results CCK-8 assay showed that compared with the control group and inhibitor-NC group， the miR-767-5p inhibitor group significantly inhibited the proliferation of MCF-7 cells（P < 0.05）. Transwell assay showed that the number of invasive cells of breast cancer cells in miR-767-5p inhibitor group was significantly lower than that in control group and inhibitor NC group （P < 0.05）. Scratch test showed that compared with the control group and inhibitor NC group， the migration rate of breast cancer cells in miR-767-5p inhibitor group decreased significantly （P < 0.05）. Luciferase reporter gene assay showed that miR-767-5p targeted IGF1 binding. Western blot showed that compared with the control group and inhibitor NC group， the expression level of E-cadherin protein in the miR-767-5p inhibitor group was significantly increased （P < 0.05）， while the expression levels of N-cadherin， MMP-2， and MMP-9 protein were significantly reduced （P < 0.05）. Compared with the control group and inhibitor-NC group， the mRNA and protein expression levels of IGF1 in the miR-767-5p inhibitor group were significantly reduced （P < 0.05）. Conclusion Suppressing the expression of miR-767-5p may inhibit the proliferation， invasion， migration and EMT of breast cancer cells by down-regulating IGF1.

Key words: breast cancer, miR-767-5p, insulin-like growth factor-1, epithelial-mesenchymal transition, migration and invasion

中图分类号:

R73-36+1

刘海英,陈峰,姚嘉. 下调胰岛素样生长因子抑制miR-767-5p的表达对乳腺癌细胞增殖、迁移、侵袭及上皮间充质转化的影响[J]. 实用医学杂志, 2023, 39(22): 2878-2884.

Haiying LIU,Feng CHEN,Jia. YAO. Suppression of miR-767-5p expression of inhibits breast cancer cell proliferation， migration， invasion and EMT through down-regulating IGF1[J]. The Journal of Practical Medicine, 2023, 39(22): 2878-2884.

图/表 8

图1

图2

图3

图4

图5

图6

图7

图8

参考文献 26

1	SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer Statistics， 2021［J］. CA Cancer J Clin， 2021， 71（1）；7-33.
2	TORRE L A， ISLAMI F， SIEGEL R L， et al. Global Cancer in Women： Burden and Trends［J］. Cancer Epidemiol Biomarkers Prev， 2017， 26（4）：444-457.
3	弭苗苗，魏晓楠，姜慧慧，等. LncRNA在乳腺癌发生，发展中的相关作用机制研究进展［J］. 检验医学与临床， 2021， 18（6）：844-847.
4	郑亚男，李梅，赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展［J］. 基础医学与临床， 2021， 41（3）：433-437.
5	靳团. 乳腺癌脑转移的信号通路和分子机制的研究进展［J］. 实用肿瘤学杂志， 2017， 31（5）：468-471.
6	PARK M， KIM D， KO S， et al. Breast Cancer Metastasis： Mechanisms and Therapeutic Implications［J］. Int J Mol Sci， 2022， 23（12）：6806.
7	CARDOSO A， UDOH K T， STATES J C. Arsenic-induced changes in miRNA expression in cancer and other diseases［J］. Toxicol Appl Pharmacol， 2020， 409（71）：115306.
8	ZHANG Q， LI T， WANG Z， et al. lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF/IGF/ERK pathway［J］. J Cell Mol Med， 2020， 24（14）：8236-8247.
9	ARMANDO C， STEFANIA O， ANNAMARIA M， et al. Molecular Signatures of the Insulin-Like Growth Factor 1-Mediated Epithelial-Mesenchymal Transition in Breast， Lung and Gastric Cancers［J］. Int J Mol Sci， 2018， 19（8）：2411-2434.
10	刘海英，陈峰，王梅，等. 乳腺癌筛选差异表达的miRNAs-mRNA及其与靶基因的关系［J］. 临床与实验病理学杂志，2022，38（5）：532-537.
11	FERLAY J， COLOMBET M， SOERJOMATARAM I， et al. Estimating the global cancer incidence and mortality in 2018： GLOBOCAN sources and methods ［J］. Int J Cancer， 2019， 144（8）：1941-1953.
12	IACOVIELLO L， BONACCIO M， GAETANO G D， et al. Epidemiology of breast cancer， a paradigm of the "common soil" hypothesis［J］. Semin Cancer Biol， 2020，72：4-10.
13	MONDAL P， MEERAN S M. Long non-coding RNAs in breast cancer metastasis［J］. Noncoding RNA Res， 2020， 5（4）：208-218.
14	ZHANG J， XU S， XU J， et al. miR-767-5p inhibits glioma proliferation and metastasis by targeting SUZ12［J］. Oncol Rep， 2019， 42（1）：55-66.
15	JIA M， LI Z， PAN M， et al. LINC-PINT Suppresses the Aggressiveness of Thyroid Cancer by Downregulating miR-767-5p to Induce TET2 Expression［J］. Mol Ther Nucleic Acids， 2020， 22：319-328.
16	LIU H， WU Y， WANG S， et al. Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p［J］. BMC Cancer， 2019， 19（1）：937.
17	WANG F， WANG X， LI J， et al. CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/JAK/STAT signaling［J］. J Biomed Sci， 2021， 28（1）：4.
18	MIERKE C T. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells［J］. Rep Prog Phys， 2019， 82（6）：064602.
19	ZIJL F V， KRUPITZA G， MIKULITS W. Initial steps of metastasis： Cell invasion and endothelial transmigration［J］. Mutat Res， 2011， 728（1-2）：23-34.
20	FAN H， WANG X， LI W， et al. ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP［J］. Genes Dev， 2020， 34（19-20）：1359-1372.
21	夏厚福，任建岗，赵怡芳. MicroRNAs与肿瘤血管生成［J］. 口腔医学研究， 2017， 33（8）：901-904.
22	SAXENA K， JOLLY M K， BALAMURUGAN K. Hypoxia， partial EMT and collective migration： Emerging culprits in metastasis［J］. Transl Oncol， 2020， 13（11）：100845.
23	JONCKHEERE S， ADAMS J， GROOTE D， et al. Epithelial-Mesenchymal Transition （EMT） as a Therapeutic Target［J］. Cells Tissues Organs， 2022， 211（2）：157-182.
24	ABAN C E， LOMBARDI A， NEIMAN G， et al. Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT［J］. Sci Rep， 2021， 11（1）：2048.
25	PENG L， WEN L， SHI Q F， et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation［J］. Cell Death Dis， 2020， 11（11）：978.
26	VAREŠLIJA D， WARD E， PURCELL S P， et al. Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype［J］. Oncogene， 2021， 40（7）：1318-1331.

[1]	宋子旭,朱光正,郭晨旭,武佳琪,张立功,钱军. SLC35A2、前叶黄素亚基2在乳腺癌中的表达及其与临床观察指标和预后的关系[J]. 实用医学杂志, 2024, 40(4): 496-502.
[2]	曾颖华,李文姬,郑莉. 经外周置入中心静脉导管后首次换药时间对乳腺癌术后患者的影响[J]. 实用医学杂志, 2024, 40(19): 2772-2777.
[3]	詹银周,陈俊衡,陈超,蔡楚源,马学珠,郭春明. 伤害感受水平指数指导瑞芬太尼输注靶浓度对接受乳腺癌根治术患者细胞免疫和缺氧诱导因子-1α的影响[J]. 实用医学杂志, 2024, 40(18): 2566-2570.
[4]	陈车,罗德红,喻皇飞,张琴,胡小池,余盛华,李亚军. 自动勾画技术在全乳内侧瘤床同步推量中的应用[J]. 实用医学杂志, 2024, 40(17): 2406-2411.
[5]	李劭晋,郑世鹏. 术前影像病理特征及肿瘤标志物预测乳腺癌前哨淋巴结转移风险[J]. 实用医学杂志, 2024, 40(17): 2418-2424.
[6]	方玲玉,胡璟骅,文俊峰,韩诗琪,王雅丽,蒲卢兰,李静佳,杨懿,邓世山,侯令密,周方方. 泛素特异性蛋白酶20、低氧诱导因子1α在乳腺癌中的表达变化及意义[J]. 实用医学杂志, 2024, 40(16): 2270-2276.
[7]	艾勇彪黄军袁杰李文仿 . 早期三阴性乳腺癌中雄激素受体表达与临床病理特征及预后的关系 [J]. 实用医学杂志, 2023, 39(8): 975-979.
[8]	袁柳青梁伟东李晓玲邓六香钟茂林 . 耳穴压豆联合经皮穴电刺激预防乳腺癌术后恶心呕吐的效果 [J]. 实用医学杂志, 2023, 39(5): 642-646.
[9]	石夕冉,王恒,何力兵,邱志强,李泓箭,徐晓雪. 多模态磁共振预测乳腺癌淋巴结转移状态的研究进展[J]. 实用医学杂志, 2023, 39(22): 2861-2865.
[10]	车雅丹,李丽霞. 小分子抗血管生成药物在晚期乳腺癌中的研究进展[J]. 实用医学杂志, 2023, 39(22): 2866-2871.
[11]	庄赵为,袁武梅,任作东,李上飞,陈明贵,曾妍. 乳腺癌患者外周血中颗粒酶B和穿孔素的表达及意义[J]. 实用医学杂志, 2023, 39(22): 2872-2877.
[12]	张正花,龚荣府,方文. 敲除成纤维细胞生长因子2基因抑制乳腺癌MCF-7细胞的增殖、迁移侵袭并促进细胞凋亡[J]. 实用医学杂志, 2023, 39(22): 2885-2890.
[13]	吕艳,郑旭,韩燕燕,高珊,李翀,耿强. CCN5基因敲降对MCF-7乳腺癌细胞增殖的影响及其作用机制[J]. 实用医学杂志, 2023, 39(22): 2898-2902.
[14]	孟瑶,刘钊,张敬,赵长啸. 应用不同重建手术保留乳腺癌患者乳头乳晕的疗效比较及预后分析[J]. 实用医学杂志, 2023, 39(22): 2903-2908.
[15]	李玉玲,杨建林,崔芝,王静,吕亚丰,曹春雨. BMI-1抑制剂PTC-596对人乳腺癌MCF-7细胞增殖、周期和凋亡的影响[J]. 实用医学杂志, 2023, 39(18): 2317-2322.